Oral lichen planus (OLP) is a complex chronic inflammatory disorder in which autocytotoxic CD8 + T cells, locally present in the affected tissue, induce basal keratinocyte apoptosis, through the release of several cytokines, such as interleukin-6 (IL-6). IL-6 is a proinflammatory cytokine that is related to alterations in lipid metabolism in psoriasis patients. Impaired lipid metabolism together with high serum levels of triglycerides have been found in association with OLP. However, the correlation between serum levels of IL-6 and dyslipidemia has not yet been studied in this disorder. The present study aimed to demonstrate the association between OLP, systemic inflammation through increased release of inflammation mediators such as IL-6 and alteration of lipid metabolism, in order to support the concept of OLP as a marker of systemic inflammation and a potential risk factor of cardiovascular morbidities. For this purpose, we designed a case-control study using a cohort of 18 patients with different clinical forms of OLP compared with 18 control group patients with other oral conditions, to identify a potential correlation between serum levels of IL-6 and serum lipid levels. High plasma serum levels of IL-6 were found to be correlated with cholesterol, high density lipoprotein cholesterol and triglyceride serum levels in the patients with OLP. There was a significant association between erosive and atrophic clinical forms of OLP and the pathological serum values of IL-6 and triglycerides, respectively, making these two parameters good predictive factors of the clinical form of OLP. Further studies of other biomarkers of systemic inflammation using larger cohorts of OLP patients are necessary in order to consider LP as a marker of systemic inflammation and to support the screening of these patients for lipid metabolism changes and treatment with specific antagonists in order to prevent cardiovascular events.
Preoperative anemia is a common finding among geriatric patients with trochanteric fractures. We assessed the dynamics of hemoglobin and the factors that influence it. A total of 780 patients with trochanteric fractures were selected. Distribution by gender showed a slightly higher proportion of female patients (64.1%). The preoperative interval ranged from a few hours to 19 days. Hospital admission period varied from 1 to 49 days. Hemoglobin ranged from 4.80 to 17.40 g/dl; 43.1% of patients had individual values below the baseline. Individually, the hemoglobin value varied from a decrease of 9.33 g/dL to an increase of 11.97 g/dL, but the total study group recorded an average decrease of 0.96 � 1.75 g/dL. Hemoglobin had a downward trend directly correlated with the preoperative interval period. Decrease in hemoglobin was correlated with the percentage of blood lymphocytes, PLT/WBC ratio, prothrombin activity and APTT ratio. A low level of hemoglobin variation was associated with a shorter preoperative interval, reduced prothrombin time, prothrombin activity ] 100, INR ] 1.50 and APTT ] 30.
Nitroglycerin has traditionally been used in medicine for over 130 years for its potent dilator effect on both venous and arterial blood vessels. Cardiovascular ischemic diseases are among the classic indications. However, the possibility to incorporate nitroglycerin in different galenic forms renders it new therapeutic potential through topical application, both in surgery and in dermatology (Raynaud syndrome, chondrodermatitis, pernio erythema, alopecia areata, ulcers of different etiologies). Nitroglycerin is used for topical treatment as 0.5%, 1% or 2% ointment, lower concentrations limiting the probability of systemic adverse effects occurence.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.